BIOLINERX
Facebook
|
Twitter
|
Linkedin
| Careers | Contact Us
search

News release
Printer Friendly Version View printer-friendly version
<< Back
BioLineRx to Present at the JMP Securities Life Sciences Conference in New York

TEL AVIV, Israel, June 15, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the JMP Securities annual life sciences equity research conference being held at the St. Regis Hotel in New York.

The BioLineRx presentation is scheduled to start at 10:30 a.m. EDT on Tuesday, June 21, 2016. A live audio webcast of the presentation will be available online at the BioLineRx Events Web Page. An archive of the event will also be available for those unable to listen live.

About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment, and has recently initiated a Phase 2 study in stem cell mobilization for allogeneic transplantation; and BL-7010 for celiac disease and gluten sensitivity, which has successfully completed a Phase 1/2 study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates, and has recently signed a collaboration agreement with MSD (known as Merck in the US and Canada) to run a Phase 2a study in pancreatic cancer using the combination of BL-8040 and Merck's KEYTRUDA®.

For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

Contacts:
PCG Advisory
Vivian Cervantes
Investor Relations
212-554-5482
vivian@pcgadvisory.com

or

Tsipi Haitovsky
Public Relations
+972-52-989892
tsipihai5@gmail.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biolinerx-to-present-at-the-jmp-securities-life-sciences-conference-in-new-york-300284943.html

SOURCE BioLineRx Ltd.


Interview with Philip Serlin, CEO
December 2016